

Contents of volume 29

No. 1

Special Issue: Consensus Symposium on Antiviral Therapy

<i>Publisher's Note</i>	1
<i>E.R. Kern, D.D. Richman</i> Foreword. Consensus symposium on combined antiviral therapy	3
<i>Review</i> <i>M.D. de Jong, C.A.B. Boucher, G.J. Galasso, M.S. Hirsch, E.R. Kern, J.M.A. Lange, D.R. Richman</i> Consensus symposium on combined antiviral therapy	5
<i>Short communications</i> <i>D.D. Richman</i> The implications of drug resistance for strategies of combination antiviral chemotherapy	31
<i>V.A. Johnson</i> Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations	35
<i>C. Shipman, Jr.</i> Analysis of drug–drug interactions: an overview	41
<i>F.G. Hayden</i> Combination antiviral therapy for respiratory virus infections	45
<i>B.E. Korba</i> In vitro evaluation of combination therapies against hepatitis B virus replication	49
<i>M.H. St. Clair, J. Millard, J. Rooney, M. Tisdale, N. Parry, B.M. Sadler, M.R. Blum, G. Painter</i> In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents	53
<i>E.R. Kern</i> Role of animal models in selecting antiviral combinations for clinical studies	57
<i>F.S. Stals, S.Sc. Wagenaar, J.S. Kloover, W.Y.R. Vanagt, C.A. Bruggeman</i> Combinations of ganciclovir and antibody for experimental CMV infections	61
<i>P.S. Lietman</i> Overview: Issues concerning the pharmacology of multiple drug regimens	65

R.J. Whitley, J.W. Gnann Jr, H.L. Weiss, S.-j. Soong

Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host

67

D.A. Jabs

Design of clinical trials for drug combinations: cytomegalovirus retinitis — foscarnet and ganciclovir. The CMV retinitis retreatment trial

69

R.B. Pollard

CMV retinitis: ganciclovir/monoclonal antibody

73

G.M. Dusheiko

Summary: antiviral treatment of hepatitis C virus

77

P.S. Reichelderfer, R.W. Coombs

Cartesian coordinate analysis of viral burden and CD4+ cell count in HIV disease: implications for clinical trial design and analysis

83

L. Perrin, B. Hirschel

Combination therapy in primary HIV infection

87

S. Vella, C. Galluzzo, G. Giannini, M.F. Pirillo, I. Duncan, H. Jacobsen, M. Andreoni, L. Sarmati, L. Ercoli
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity

91

H. Jacobsen, M. Haenggi, M. Ott, I.B. Duncan, M. Andreoni, S. Vella, J. Mous

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials

95

A.C. Collier, R.W. Coombs, D.A. Schoenfeld, R. Bassett, A. Baruch, L. Corey

Combination therapy with zidovudine, didanosine and saquinavir

99

R.B. Pollard

D4T nucleoside combinations for HIV

101

M.C. Sneller

Consensus symposium on combined antiviral therapy; Overview of interferon and IL-2 combinations for the treatment of HIV infection

105

F. Biron, F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugier, J. Grange, S. Malley, F. Hamed-Sangsari, J. Vila

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals

111

W. Bahlman

Innovative combination clinical trial designs/patient compliance: A community perspective

115

C. McLaren, M. Elkins, M. Salgo, M. Myers, S. Benoit, M. Warburg

Inter-Company Collaboration for AIDS Drug Development: perspective on combination studies

119

No. 2

Review

J.M. Colacino

- Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU) 125

Mini review

R. Cirelli, K. Herne, M. McCrary, P. Lee, S.K. Tying

- Famciclovir: review of clinical efficacy and safety 141

Research articles

M. Wachsmann, B.G. Petty, K.C. Cundy, H.S. Jaffe, P.E. Fisher, A. Pastelak, P.S. Lietman

- Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects 153

R. Ikeda, Y. Haraguchi, Y. Ikeda, S. Kondo, T. Takeuchi, H. Hoshino

- Inhibition of human immunodeficiency virus type 1 infectivity by a new amine bellenamine 163

P.L. Black, M.A. Ussery, S. Barney, R. Wittrock, P. DeMarsh, G.B. Dreyer, S.R. Petteway, Jr., P. DalMonte, J. Baldoni, D.M. Lambert

- Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice 175

F. Pica, A. Rossi, N. Santirocco, A. Palamara, E. Garaci, M.G. Santoro

- Effect of combined α IFN and prostaglandin A₁ treatment on vesicular stomatitis virus replication and heat shock protein synthesis in epithelial cells 187

E.G. Saravolac, B. Kournikakis, L. Gorotn, J.P. Wong

- Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon- γ 199

K. De Vreese, D. Reymen, P. Griffin, A. Steinkasserer, G. Werner, G.J. Bridger, J. Esté, W. James, G.W. Henson, J. Desmyter, J. Anné, E. De Clercq

- The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding 209

M. Marchetti, C. Longhi, M.P. Conte, S. Pisani, P. Valenti, L. Seganti

- Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells 221

H. Yang, R.L. Drain, C.A. Franco, J.M. Clark

- Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice 233

M. Daibata, E.-M. Enzinger, J.E. Monroe, R.E. Kilkuskie, A.K. Field, C. Mulder

- Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication 243

A. Faraj, R.F. Schinazi, M.-Y. Xie, G. Gosselin, J.-L. Imbach, J.-P. Sommadossi

- Selective protection of toxicity of 2',3'-dideoxypyrimidine nucleoside analogs by β -D-uridine in human granulocyte-macrophage progenitor cells 261

J.A. Turpin, C.A. Schaeffer, M. Bu, L. Graham, R.W. Buckheit Jr, D. Clanton, W.G. Rice

- Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor 269

P.J. Patel, A.-H. Ghanem, W.I. Higuchi, V. Srinivasan, E.R. Kern

- Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept 279

J.M. Gwaltney Jr., R.M. Buier, J.L. Rogers

The influence of signal variation, bias, noise and effect size on statistical significance in treatment studies of the common cold 287

J.A. Esté, K. De Vreese, M. Witvrouw, J.-C. Schmit, A.-M. Vandamme, J. Anné, J. Desmyter, G.W. Henson, G. Bridger, E. De Clercq

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1 297

Short communications

M. Jashés, M. González, M. López-Lastra, E. De Clercq, A. Sandino

Inhibitors of infectious pancreatic necrosis virus (IPNV) replication 309

Author index 313

Subject index 317

Volume contents 323